Please sign in to follow a disease.
Lynch syndrome
MONDO:0005835An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.
Also known as: Hereditary colorectal endometrial cancer syndrome, Hereditary non-polyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2), Hereditary nonpolyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2), Lynch syndrome, familial non-polyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2), hereditary defective mismatch repair syndrome
2983 clinical trials for this condition and its sub-types, 81 tagged with Lynch syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lynch syndrome
-
Lynch syndrome 1 5 trials
-
Lynch syndrome 2 3 trials
-
Lynch syndrome 4 0 trials
-
Lynch syndrome 5 0 trials
-
Lynch syndrome 8 0 trials
-
Can a new nucleotide analogue boost cancer treatment?
Disease control Stopped earlyThis trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…
Phase 1/2 • Sponsor: NuCana plc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Experimental vaccine aims to shrink colorectal tumors before surgery
Disease control Stopped earlyThis trial tested a vaccine called PD1-Vaxx given before surgery to people with a specific type of colorectal cancer (MSI-high). The goal was to see if the vaccine could shrink tumors, measured by how many cancer cells remained after treatment. Only 3 people took part, and the st…
Phase 2 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental triple therapy for advanced cancers shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Colon cancer combo trial ends early – only one patient enrolled
Disease control Stopped earlyThis study tested a combination of two drugs (regorafenib and pembrolizumab) for people with a specific type of advanced colorectal cancer called MSI-H. The goal was to see if the combination worked better than pembrolizumab alone. The trial was stopped early after enrolling only…
Phase 2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC